GlassScriptPhysician profile
Helda Barakat
NPI 1154571529
$4,012.19
in general payments reported to CMS, 2019-2025
44 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $221 · 2021: $364 · 2022: $455 · 2023: $751 · 2024: $980 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.89 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.01 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.34 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $320.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $257.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $244.79 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $155.08 | 2022-2025 | |
| Amgen INC. | $153.63 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $141.13 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $116.01 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.34 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.84 | 2023-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $94.52 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $90.38 | 2023-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $84.62 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $82.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $72.13 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $63.96 | 2019-2025 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Vanda Pharmaceuticals INC. | $63.82 | 2025 | Fanapt |
| Astellas Pharma US INC | $59.78 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $51.90 | 2023-2024 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $51.59 | 2022 | |
| Axsome Therapeutics, INC. | $50.66 | 2024-2025 | Auvelity |
| Radius Health, INC. | $50.56 | 2025 | |
| Amneal Pharmaceuticals LLC | $50.51 | 2021-2023 | Unithroid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.76 | 2024-2025 | Rexulti |
| Edwards Lifesciences Corporation | $43.71 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Dexcom, INC. | $35.04 | 2023-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $31.77 | 2023-2024 | Gemtesa |
| Allergan, INC. | $24.69 | 2019-2020 | |
| Amarin Pharma, INC. | $24.00 | 2019-2022 | |
| Esperion Therapeutics, INC. | $23.83 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $22.86 | 2024 | Crysvita |
| Supernus Pharmaceuticals, INC. | $21.65 | 2025 | Qelbree, Xyosted, Tlando |
| Phathom Pharmaceuticals, INC. | $19.62 | 2025 | Voquezna |
| Lundbeck LLC | $17.20 | 2024 | Rexulti |
| Halozyme INC | $16.23 | 2023 | |
| Eisai INC. | $15.11 | 2021 | |
| Ardelyx, INC. | $15.03 | 2025 | Ibsrela |
| Neurocrine Biosciences, INC. | $14.90 | 2025 | |
| Ironwood Pharmaceuticals, INC | $14.69 | 2024 | |
| Vifor Pharma, INC. | $14.32 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.07 | 2021 | |
| Corcept Therapeutics | $12.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helda Barakat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.